NCT05077124

Safe and Timely Antithrombotic Removal (STAR) Registry

Safe and Timely Antithrombotic Removal (STAR) Registry: International Registry on the Use of CytoSorb for Removal of Antithrombotic Agents in the Acute Hospital Setting

• Status: Recruiting
• Phase: —
• Study type: Observational
• Enrollment: 1,000 (estimated)
• Sponsor: CytoSorbents, Inc · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This registry will capture real-world clinical use patterns and associated clinical outcomes with the use of CytoSorb for the removal of antithrombotic agents.

Detailed description

The STAR Registry will collect patient-level clinical data on antithrombotic removal with CytoSorb. The decision to use CytoSorb in this clinical setting is based on the clinical rationale of mitigating the high risk of bleeding events that is directly linked to the presence of the antithrombotic agent. This registry is to capture real-world clinical use patterns and associated clinical outcomes with the use of CytoSorb. Data of retrospective and prospective patients will be included in the registry. Safety will be assessed by collection of (at least possibly) device-related adverse events. Data collection is done up to 30 days post-operation.

Conditions

• Hemorrhage, Surgical
• Hemorrhage Postoperative
• Blood Loss, Surgical
• Blood Loss, Postoperative

Interventions

Type	Name	Description
DEVICE	CytoSorb	Sorbent hemoperfusion system

Timeline

• Start date: 2021-09-30
• Primary completion: 2025-09-30
• Completion: 2025-09-30
• First posted: 2021-10-14
• Last updated: 2025-07-16

Locations

30 sites across 6 countries: Austria, Belgium, Germany, Sweden, Switzerland, United Kingdom